PHARMACY

NCPA: Ohio pharmacists seek legislative relief from PBM practices

BY Antoinette Alexander

ALEXANDRIA, Va. — Legislative relief that would result in a more balanced business relationship between Ohio community pharmacists and PBMs is critical, according to the National Community Pharmacists Association.

“Across the Buckeye State 549 independent community pharmacies serve patients, employ 5,435 people and contribute greatly to local and state tax revenue,” stated NCPA CEO B. Douglas Hoey. “The viability of these small businesses is being undermined by the practices of billion-dollar companies known as pharmacy benefit managers, hired by most health plans to administer prescription drug benefits. For Ohioans, their communities and the future of these pharmacies, we encourage lawmakers to swiftly enact common-sense reforms to achieve a more balanced business relationship between PBMs and community pharmacies.”

Hoey singled out three trends that are particularly in need of legislation and further oversight:

  • First, in order to care for Ohio patients covered by a given health plan, community pharmacists must sign take-it-or-leave-it contracts from Fortune 500 PBMs. PBMs use the authority imposed by these contracts to determine how they will reimburse pharmacies, especially for generic drugs, which account for nearly 80% of drugs dispensed. Thus, these small business providers are “flying blind” in terms of taking into account the operating costs of their prescription drug inventory, NCPA stated;
  • Second, a pharmacy’s acquisition cost for scores of generic drugs are rising by as much as 600%, 1,000% or more, but the PBMs continue to reimburse community pharmacies at an outdated, lower price, NCPA stated. Pharmacists report repeatedly being faced with loses of $40, $60, $100 or more per prescription as the PBM waits several months before updating its reimbursement rates — and never retroactively; and
  • Third, by reimbursing pharmacies at low rates and charging health plans at much higher rates — a practice known as “spread pricing” — the PBMs generate enormous profits while increasing insurance costs for employers, government agencies and consumers. The largest PBM generates approximately $100 billion in annual revenue and its CEO received more than $100 million in compensation over five years, Forbes.com calculated. Legislation increasing transparency in pharmacy benefit management could reduce the cost of PBM spread pricing and keep more health care dollars within Ohio.

NCPA noted that a recent Fortune magazine article documented inflated costs and other problems arising from the lack of transparency into drug benefit managers.

“NCPA is proud to support the work of the Ohio Pharmacists Association and all Ohio pharmacists in this effort,” Hoey added. 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

PHARMACY

Perrigo approved for generic Prandin

BY Ryan Chavis

DUBLIN — Perrigo Co. announced that it received final approval from the Food and Drug Administration for repaglinide tablets — a generic version of Prandin tablets — in 1-mg and 2-mg strengths. The company has started shipment of the drug. Perrigo previously launched the 0.5-mg strength in 2013.

"This approval shows the talent and expertise of our R&D and regulatory affairs departments. This is another example of Perrigo’s commitment to bring new products to market and deliver on our mission to provide quality, affordable health care to consumers," said Joseph C. Papa, Perrigo’s Chairman, president and CEO.

Prandin is used to improve glycemic control in adults with Type 2 diabetes. Annuals sales of Prandin tablets are approximately $250 million, according to Symphony Health Solutions.

 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

PHARMACY

Hi-Tech Pharmacal gets approval for bromfenac

BY Ryan Chavis

AMITYVILLE, N.Y. — Hi-Tech Pharmacal Co., a specialty pharmaceuticals company, on Thursday announced that it was granted final approval from the Food and Drug Administration for bromfenac ophthalmic solution 0.09% (once-a-day), a generic version of ISTA Pharmaceuticals’ Bromday ophthalmic solution, 0.09%.

The product is used to treat post-op inflammation and reduction of ocular pain in patients who have had cataract surgery. The company plans to launch the product immediately.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES